Matthew Herper and Elaine Chen

BioTech

Eli Lilly CEO says the company sees ‘significant common cause’ with Trump administration

SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration,

Matthew Herper and Elaine Chen January 14, 2025

BioTech

Pfizer says it will advance once-daily GLP-1 pill after all

Pfizer said Thursday that it plans to advance a new, once-a-day formulation of its experimental obesity drug danuglipron, meant to be a pill version in

Matthew Herper and Elaine Chen July 11, 2024

BioTech

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted to a smaller group

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts

Matthew Herper and Elaine Chen June 6, 2024

BioTech

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575 million, lowering hopes of a buyout

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech

Matthew Herper and Elaine Chen May 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Matthew Herper and Elaine Chen

Eli Lilly CEO says the company sees ‘significant common cause’ with Trump administration

Pfizer says it will advance once-daily GLP-1 pill after all

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted to a smaller group

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575 million, lowering hopes of a buyout

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe